Abstract:Background: 12N-benzyl matrinic acid analogues had been identified to be a novel scaffold of anti-HCV agents with a specific mechanism, and the representative compound 1 demonstrated a moderate anti-HCV activity. The intensive structure-activity relationship of this kind of compounds is explored so as to obtain anti-HCV candidates with good druglike nature. Results: Taking compound 1 as the lead, 32 compounds (of which 27 were novel) with diverse structures on the 11-side chain, including methyl matrinate, matrinol, matrinic butane, (Z)-methyl Δβγ-matrinic crotonate derivatives were synthesized and evaluated for their anti-HCV activities. Among all the compounds, matrinol 7a demonstrated potential potency with a greatly improved SI value of 136. Pharmacokinetic studies of 7a showed the potential for oral administration that would allow further in vivo safety studies. The free hydroxyl arm in 7a made it possible to prepare pro-drugs for the potential in the treatment of HCV infection. Conclusions: 27 novel 12N-substituted matrinol derivatives were prepared. The SAR study indicated that the introduction of electron-donating substitutions on the benzene ring was helpful for the anti-HCV activity, and the unsaturated 11-side chain might not be favorable for the activity. This study provided powerful information on further strategic optimization and development of this kind of compounds into a novel family of anti-HCV agents. Graphical abstract Matrinol derivatives as a class of novel anti-HCV agents.

Potent Bisimidazole-Based HCV NS5A Inhibitors Bearing Annulated Tricyclic Motifs

Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Discovery of Novel Potent HCV NS5B Polymerase Non-Nucleoside Inhibitors Bearing a Fused Benzofuran Scaffold.

HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives.

Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents

Discovery of Ravidasvir (PPI-668) As a Potent Pan-Genotypic HCV NS5A Inhibitor.

Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor

Tetrazole and Triazole As Bioisosteres of Carboxylic Acid: Discovery of Diketo Tetrazoles and Diketo Triazoles As Anti-Hcv Agents.

Combined 3D-QSAR, Molecular Docking and Molecular Dynamics Study on the Benzimidazole Inhibitors Targeting HCV NS5B Polymerase

Synthesis and biological evaluation of novel pentacyclic triterpene α-cyclodextrin conjugates as HCV entry inhibitors

Design and synthesis of HCV agents with sequential triple inhibitory potentials

Structure–activity relationship studies on quinoxalin-2(1 H )-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870

Synthesis and biological evaluation of tricyclic matrinic derivatives as a class of novel anti-HCV agents

2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action

Bioisosteric replacement of the carboxylic acid group in Hepatitis-C virus NS5B thumb site II inhibitors: phenylalanine derivatives

Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease

Flavonoid-triazolyl hybrids as potential anti-hepatitis C virus agents: Synthesis and biological evaluation

Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity

Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Dimers as HCV Entry Inhibitors